PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation

Biochemical and Biophysical Research Communications

Volumn 424, Issue 3, 2012, Pages 421-426

  Qiao, Jingbo ^a   Paul, Pritha ^a,b   Lee, Sora ^a,b   Qiao, Lan ^a   Josifi, Erlena ^a   Tiao, Joshua R ^a   Chung, Dai H ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Differentiation; ERK; Neuroblastoma; PI3K; Retinoic acid

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; P21 ACTIVATED KINASE; PROTEIN KINASE B; PROTEIN P27; RETINOIC ACID;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL;

CELL DIFFERENTIATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G0 PHASE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; NEUROBLASTOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TRETINOIN;

EID: 84864739923     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.06.125     Document Type: Article

References (31)

1. Duester G. Retinoic acid synthesis and signaling during early organogenesis. Cell 2008, 134:921-931.
2. Noy N. Between death and survival: retinoic acid in regulation of apoptosis. Annu. Rev. Nutr. 2010, 30:201-217.
3. Nagpal S. Retinoids: inducers of tumor/growth suppressors. J. Invest. Dermatol. 2004, 123:xx-xxi.
4. Ma Y., Koza-Taylor P.H., DiMattia D.A., Hames L., Fu H., Dragnev K.H., Turi T., Beebe J.S., Freemantle S.J., Dmitrovsky E. Microarray analysis uncovers retinoid targets in human bronchial epithelial cells. Oncogene 2003, 22:4924-4932.
5. Keedwell R.G., Zhao Y., Hammond L.A., Qin S., Tsang K.Y., Reitmair A., Molina Y., Okawa Y., Atangan L.I., Shurland D.L., Wen K., Wallace D.M., Bird R., Chandraratna R.A., Brown G. A retinoid-related molecule that does not bind to classical retinoid receptors potently induces apoptosis in human prostate cancer cells through rapid caspase activation. Cancer Res. 2004, 64:3302-3312.
6. Reynolds C.P., Wang Y., Melton L.J., Einhorn P.A., Slamon D.J., Maurer B.J. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med. Pediatr. Oncol. 2000, 35:597-602.
7. Villablanca J.G., Khan A.A., Avramis V.I., Seeger R.C., Matthay K.K., Ramsay N.K., Reynolds C.P. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J. Clin. Oncol. 1995, 13:894-901.
8. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
9. Masia S., Alvarez S., de Lera A.R., Barettino D. Rapid, nongenomic actions of retinoic acid on phosphatidylinositol-3-kinase signaling pathway mediated by the retinoic acid receptor. Mol. Endocrinol. 2007, 21:2391-2402.
10. Pan J., Kao Y.L., Joshi S., Jeetendran S., Dipette D., Singh U.S. Activation of Rac1 by phosphatidylinositol 3-kinase in vivo: role in activation of mitogen-activated protein kinase (MAPK) pathways and retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J. Neurochem. 2005, 93:571-583.
11. Bodart J.F. Extracellular-regulated kinase-mitogen-activated protein kinase cascade: unsolved issues. J. Cell. Biochem. 2010, 109:850-857.
12. Fulda S. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Curr. Cancer Drug Targets 2009, 9:729-737.
13. Holzel M., Huang S., Koster J., Ora I., Lakeman A., Caron H., Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C., Messiaen L., Versteeg R., Bernards R. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010, 142:218-229.
14. Caino M.C., Meshki J., Kazanietz M.G. Hallmarks for senescence in carcinogenesis: novel signaling players. Apoptosis 2009, 14:392-408.
15. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., Reynolds C.P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 1999, 341:1165-1173.
16. Kang J.H., Rychahou P.G., Ishola T.A., Qiao J., Evers B.M., Chung D.H. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem. Biophys. Res. Commun. 2006, 351:192-197.
17. Wang L., Mear J.P., Kuan C.Y., Colbert M.C. Retinoic acid induces CDK inhibitors and growth arrest specific (Gas) genes in neural crest cells. Dev. Growth Differ. 2005, 47:119-130.
18. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?. Trends Cell Biol. 2003, 13:65-70.
19. Nakamura M., Matsuo T., Stauffer J., Neckers L., Thiele C.J. Retinoic acid decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 phosphorylation and an N-myc-independent decrease in Skp2. Cell Death Differ. 2003, 10:230-239.
20. Andreu E.J., Lledo E., Poch E., Ivorra C., Albero M.P., Martinez-Climent J.A., Montiel-Duarte C., Rifon J., Perez-Calvo J., Arbona C., Prosper F., Perez-Roger I. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res. 2005, 65:3264-3272.
21. Hammond L.A., Brown G., Keedwell R.G., Durham J., Chandraratna R.A. The prospects of retinoids in the treatment of prostate cancer. Anticancer Drugs 2002, 13:781-790.
22. Lu X.P., Fanjul A., Picard N., Pfahl M., Rungta D., Nared-Hood K., Carter B., Piedrafita J., Tang S., Fabbrizio E., Pfahl M. Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nat. Med. 1997, 3:686-690.
23. Armstrong J.L., Redfern C.P., Veal G.J. 13-cis retinoic acid and isomerisation in paediatric oncology-is changing shape the key to success?. Biochem. Pharmacol. 2005, 69:1299-1306.
24. Gianni M., Kopf E., Bastien J., Oulad-Abdelghani M., Garattini E., Chambon P., Rochette-Egly C. Down-regulation of the phosphatidylinositol 3-kinase/Akt pathway is involved in retinoic acid-induced phosphorylation, degradation, and transcriptional activity of retinoic acid receptor gamma 2. J. Biol. Chem. 2002, 277:24859-24862.
25. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
26. Zancai P., Dal Col J., Piccinin S., Guidoboni M., Cariati R., Rizzo S., Boiocchi M., Maestro R., Dolcetti R. Retinoic acid stabilizes p27Kip1 in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45Skp2 and Cks1 proteins. Oncogene 2005, 24:2483-2494.
27. Reagan-Shaw S., Ahmad N. RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. Cancer Res. 2006, 66:1062-1069.
28. Ekholm S.V., Reed S.I. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr. Opin. Cell Biol. 2000, 12:676-684.
29. Shin I., Yakes F.M., Rojo F., Shin N.Y., Bakin A.V., Baselga J., Arteaga C.L. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat. Med. 2002, 8:1145-1152.
30. Viglietto G., Motti M.L., Bruni P., Melillo R.M., D'Alessio A., Califano D., Vinci F., Chiappetta G., Tsichlis P., Bellacosa A., Fusco A., Santoro M. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 2002, 8:1136-1144.
31. Brandts C.H., Bilanges B., Hare G., McCormick F., Stokoe D. Phosphorylation-independent stabilization of p27kip1 by the phosphoinositide 3-kinase pathway in glioblastoma cells. J. Biol. Chem. 2005, 280:2012-2019.